Emerging role for NK cells in the pathogenesis of inflammatory arthropathies

Autoimmunity Reviews

Volumn 10, Issue 10, 2011, Pages 577-581

  Conigliaro, Paola ^a   Scrivo, Rossana ^b   Valesini, Guido ^b   Perricone, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autoimmunity; Immune mediated diseases; Natural killer cells; Rheumatoid arthritis; Spondyloarthropathies

Indexed keywords

CD56 ANTIGEN; IMMUNOGLOBULIN RECEPTOR;

ADAPTIVE IMMUNITY; ALLOTYPE; ARTHRITIDE; ARTHRITIS; ARTHROPATHY; BONE INJURY; CELL FUNCTION; CELL TYPE; DENDRITIC CELL; FIBROBLAST; HUMAN; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PSORIASIS; REVIEW; SKIN DEFECT; SPONDYLOARTHROPATHY; SYNOVIUM; TH1 CELL;

ANIMALS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOMODULATION; INFLAMMATION; KILLER CELLS, NATURAL; POLYMORPHISM, GENETIC; RECEPTORS, NATURAL KILLER CELL; SPONDYLITIS, ANKYLOSING; SYNOVIAL MEMBRANE; TH1 CELLS;

EID: 80051671636     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.017     Document Type: Review

References (58)

1. Orange J.S., Ballas Z.K. Natural killer cells in human health and disease. Clin Immunol 2006, 118:1-10.
2. Takasugi M., Mickey M.R., Terasaki P.I. Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res 1973, 33:2898-2902.
3. Robertson M.J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990, 76:2421-2438.
4. Lanier L.L. Back to the future-defining NK cells and T cells. Eur J Immunol 2007, 37:1424-1426.
5. Colucci F., Di Santo J.P., Leibson P.J. Natural killer cell activation in mice and men: different triggers for similar weapons?. Nat Immunol 2002, 3:807-813.
6. Gardiner C.M. Killer cell immunoglobulin-like receptors on NK cells: the how, where and why. Int J Immunogenet 2008, 35:1-8.
7. Paust S., Gill H.S., Wang B.Z., Flynn M.P., Moseman E.A., Senman B., et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010, 11:1127-1135.
8. Fort M.M., Leach M.W., Rennick D.M. A role for NK cells as regulators of CD4+ T cells in a transfer model of colitis. J Immunol 1998, 161:3256-3261.
9. Takeda K., Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993, 177:155-164.
10. Lee I.F., Qin H., Trudeau J., Dutz J., Tan R. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J Immunol 2004, 172:937-942.
11. Maruyama T., Watanabe K., Takei I., Kasuga A., Shimada A., Yanagawa T., et al. Anti-asialo GM1 antibody suppression of cyclophosphamide-induced diabetes in NOD mice. Diabetes Res 1991, 17:37-41.
12. Poirot L., Benoist C., Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci U S A 2004, 101:8102-8107.
13. Shi F.D., Wang H.B., Li H., Hong S., Taniguchi M., Link H., et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000, 1:245-251.
14. Setiady Y.Y., Pramoonjago P., Tung K.S. Requirements of NK cells and proinflammatory cytokines in T cell-dependent neonatal autoimmune ovarian disease triggered by immune complex. J Immunol 2004, 173:1051-1058.
15. Zhang B., Yamamura T., Kondo T., Fujiwara M., Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997, 186:1677-1687.
16. Winkler-Pickett R., Young H.A., Cherry J.M., Diehl J., Wine J., Back T., et al. In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J Immunol 2008, 180:4495-4506.
17. Matsumoto Y., Kohyama K., Aikawa Y., Shin T., Kawazoe Y., Suzuki Y., et al. Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur J Immunol 1998, 28:1681-1688.
18. Park Y.W., Kee S.J., Cho Y.N., Lee E.H., Lee H.Y., Kim E.M., et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1753-1763.
19. Cameron A.L., Kirby B., Griffiths C.E. Circulating natural killer cells in psoriasis. Br J Dermatol 2003, 149:160-164.
20. Ottaviani C., Nasorri F., Bedini C., de Pita O., Girolomoni G., Cavani A. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006, 36:118-128.
21. Perricone C., De Carolis C., Giacomelli R., Zaccari G., Cipriani P., Bizzi E., et al. High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. Rheumatology (Oxford) 2007, 46:1574-1578.
22. Perricone R., Perricone C., De Carolis C., Shoenfeld Y. NK cells in autoimmunity: a two-edg'd weapon of the immune system. Autoimmun Rev 2008, 7:384-390.
23. Dalbeth N., Callan M.F. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 2002, 46:1763-1772.
24. Pridgeon C., Lennon G.P., Pazmany L., Thompson R.N., Christmas S.E., Moots R.J. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright, CD94bright, CD158negative phenotype. Rheumatology (Oxford) 2003, 42:870-878.
25. Dalbeth N., Gundle R., Davies R.J., Lee Y.C., McMichael A.J., Callan M.F. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004, 173:6418-6426.
26. Tak P.P., Kummer J.A., Hack C.E., Daha M.R., Smeets T.J., Erkelens G.W., et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994, 37:1735-1743.
27. Muller-Ladner U., Kriegsmann J., Tschopp J., Gay R.E., Gay S. Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:477-484.
28. Goldbach-Mansky R., Suson S., Wesley R., Hack C.E., El-Gabalawy H.S., Tak P.P. Raised granzyme B levels are associated with erosions in patients with early rheumatoid factor positive rheumatoid arthritis. Ann Rheum Dis 2005, 64:715-721.
29. Kraan M.C., Haringman J.J., Weedon H., Barg E.C., Smith M.D., Ahern M.J., et al. T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004, 63:483-488.
30. Shibatomi K., Ida H., Yamasaki S., Nakashima T., Origuchi T., Kawakami A., et al. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum 2001, 44:884-892.
31. Aramaki T., Ida H., Izumi Y., Fujikawa K., Huang M., Arima K., et al. A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod Rheumatol 2009, 19:245-252.
32. Ahern DJ, Brennan FM The role of Natural Killer cells in the pathogenesis of rheumatoid arthritis: Major contributors or essential homeostatic modulators?. Immunol Lett 2011, 136:115-121.
33. Lo C.K., Lam Q.L., Sun L., Wang S., Ko K.H., Xu H., et al. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. Arthritis Rheum 2008, 58:2700-2711.
34. Soderstrom K., Stein E., Colmenero P., Purath U., Muller-Ladner U., de Matos C.T., et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A 2010, 107:13028-13033.
35. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22:633-640.
36. Zhang A.L., Colmenero P., Purath U., Teixeira de Matos C., Hueber W., Klareskog L., et al. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 2007, 110:2484-2493.
37. Chan A., Filer A., Parsonage G., Kollnberger S., Gundle R., Buckley C.D., et al. Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cells. Arthritis Rheum 2008, 58:707-717.
38. Marcenaro E., Ferranti B., Moretta A. NK-DC interaction: on the usefulness of auto-aggression. Autoimmun Rev 2005, 4:520-525.
39. Poggi A., Zocchi M.R. Human natural killer lymphocytes through the engagement of natural cytotoxicity receptors and NKG2D can trigger self-aggression. Autoimmun Rev 2007, 6:295-299.
40. Piccioli D., Sbrana S., Melandri E., Valiante N.M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002, 195:335-341.
41. Yen J.H., Lin C.H., Tsai W.C., Wu C.C., Ou T.T., Hu C.J., et al. Killer cell immunoglobulin-like receptor gene's repertoire in rheumatoid arthritis. Scand J Rheumatol 2006, 35:124-127.
42. Ehrenfeld M. Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 2010, 9:A325-A329.
43. Akkoc N. Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review. Curr Rheumatol Rep 2008, 10:371-378.
44. FitzGerald O., McInnes I. Spondyloarthropathy: disease at the crossroads of immunity. Best Pract Res Clin Rheumatol 2006, 20:949-967.
45. Veale D.J., Ritchlin C., FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005, 64. Suppl 2:ii26-9.
46. McGonagle D., Lories R.J., Tan A.L., Benjamin M. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007, 56:2482-2491.
47. Martin M.P., Nelson G., Lee J.H., Pellett F., Gao X., Wade J., et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002, 169:2818-2822.
48. Chan A.T., Kollnberger S.D., Wedderburn L.R., Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 2005, 52:3586-3595.
49. Diaz-Pena R., Vidal-Castineira J.R., Alonso-Arias R., Suarez-Alvarez B., Vicario J.L., Solana R., et al. Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis. Arthritis Rheum 2010, 62:1000-1006.
50. Vilches C., Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002, 20:217-251.
51. Scrivo R., Morrone S., Spadaro A., Santoni A., Valesini G. Evaluation of degranulation and cytokine production in natural killer cells from spondyloarthritis patients at single-cell level. Cytometry B Clin Cytom 2011, 80:22-27.
52. Kollnberger S., Chan A., Sun M.Y., Chen L.Y., Wright C., di Gleria K., et al. Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur J Immunol 2007, 37:1313-1322.
53. Spadaro A., Scrivo R., Moretti T., Bernardini G., Riccieri V., Taccari E., et al. Natural killer cells and gamma/delta T cells in synovial fluid and in peripheral blood of patients with psoriatic arthritis. Clin Exp Rheumatol 2004, 22:389-394.
54. Giacomelli R., Passacantando A., Frieri G., Parzanese I., D'Alo S., Vernia P., et al. Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients. Clin Exp Immunol 1999, 115:72-77.
55. Steel A.W., Mela C.M., Lindsay J.O., Gazzard B.G., Goodier M.R. Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment Pharmacol Ther 2011, 33:115-126.
56. Rodacki M., Svoren B., Butty V., Besse W., Laffel L., Benoist C., et al. Altered natural killer cells in type 1 diabetic patients. Diabetes 2007, 56:177-185.
57. Vranes Z., Poljakovic Z., Marusic M. Natural killer cell number and activity in multiple sclerosis. J Neurol Sci 1989, 94:115-123.
58. Rauch H.C., Montgomery I.N., Kaplan J. Natural killer cell activity in multiple sclerosis and myasthenia gravis. Immunol Invest 1985, 14:427-434.